sameAs
Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise reviewProfile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infectionFour weeks of paritaprevir/ritonavir/ombitasvir plus dasabuvir encountering dengue fever resulted in sustained virological response in an HCV patient: A case report.Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System.Effect of co-medications on paritaprevir, ritonavir, ombitasvir, dasabuvir and ribavirin pharmacokinetics: analysis of data from seven Phase II/III trials.Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemiaEffectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study.Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir.Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir.Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets): All-Oral Fixed Combination Approved for Genotype 1 Chronic Hepatitis C InfectionExposure-Safety Response Relationship for Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III Studies.Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-RitonavirPopulation Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 StudiesDrug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without DasabuvirOmbitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma.On-Treatment Elevation in Hepatic Transaminases during HCV Treatment with Ombitasvir, Paritaprevir, Dasabuvir, Ritonavir, and Ribavirin: A Case Series.Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers.Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvirDrug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus LamivudineRandomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis.Pharmacokinetic Evaluation of Darunavir Administered Once or Twice Daily in Combination with Ritonavir or the Three-Direct-Acting Antiviral Regimen of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults Coinfected with Hepatitis C and Human ImDrug Induced Pneumonitis Secondary to Treatment with Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir (VIEKIRA PAK®) for Chronic Hepatitis C: Case Report of an Unexpected Life-Threatening Adverse ReactionOmbitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection.Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C.Safety and efficacy of ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens.Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir.Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients.Exposure-Response Relationship for Ombitasvir and Paritaprevir/Ritonavir in Hepatitis C Virus Subgenotype 1b-Infected Japanese Patients in the Phase 3 Randomized GIFT-I Study.Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection.Working together to tackle HCV infection: ombitasvir/paritaprevir/ritonavir and dasabuvir combination.Real world efficacy and safety of ombitasvir, Paritaprevir/r+Dasabuvir+Ribavirin IN genotype 1B patients with HCV liver cirrhosis.Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan.New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir.Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study.Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America.Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry.
P921
Q26747705-2A6A31F1-D087-4AC4-B271-B1B288F2451EQ26775825-C91B1CD4-084E-47B0-A075-EF882FF534C4Q30368260-933BCAF5-AE45-4DCF-A33C-E3C4DEA1D5B1Q30841159-0E5532D8-0230-4154-BBF4-45AD2CA0841DQ31126062-4DACD61D-A532-4C5F-A1A6-B042F85AA32DQ33424963-F69A0ED6-49E7-447A-8CE9-872AEEAC4ED1Q33883646-3EC39AEE-CEBF-436E-8395-D63639D9A11BQ36052284-9BE41B0B-ECEC-4358-8936-064A2AF3AD1DQ36158361-4AEF1B5F-6A5A-4255-8303-97A8E856D4DBQ36333772-F3C2A4B6-36A1-4301-8E0F-343D302DDD6BQ36335281-4B5FFBB5-6C6D-4423-9A3A-3FCBAD8824F6Q36438920-2CE28896-CE87-480A-85B0-879454DB5E8EQ36445132-562C8179-1DC5-4957-ACE2-31A2C09DB233Q36571969-37DA114D-87AA-4B72-8285-50FDFEFCADDFQ36621548-E4E2EB75-CAF0-4EBE-BCB5-031D587CF9CCQ36985508-8E9B5342-45BA-410F-ABF1-00DA7FB0E2DEQ37067118-100A4FDD-C0D0-4E8C-B78F-2261BBA256E7Q37257317-7B73B51F-D270-4A60-A088-892433559465Q37287684-279BDD6F-5BD7-4B4A-83CF-9973FA592CCAQ37309080-076916A3-2663-4DA1-9998-448C758CE262Q37612932-556933DF-0F09-4FDC-9DD5-E5942BFD8240Q37734343-037F0CFC-F28D-4C30-BBF6-D4079CC9386FQ38235178-04A894CC-3B34-42AF-A0E1-1D3E6EEF2B0CQ38262922-C1F1D3EF-647A-436A-9E10-CBF5421A986BQ38267912-CE952839-6CF6-4FDD-9475-C2230E122E70Q38355057-AE34532E-1421-444A-8965-B84B6EC7E5BEQ38367590-E7BB241D-E558-4147-A5F1-438DD901EF95Q38376454-98FA8DEE-4ECF-41E2-8343-6DBCDF7056ACQ38393581-90636B44-2030-4E10-8428-950CE6C2D7DAQ38415846-FD3148EE-2E2C-447A-87B3-BE53E3F27057Q38522622-60DF1828-8E53-4700-8524-7CA628D6B094Q38534091-337BB83A-F990-46E0-AC22-DAE08AFDAF8BQ38620762-E65B6A31-961D-4C4F-96C7-77847C369892Q38649797-E89CE134-D436-4AF7-BACB-0D5F768D1A46Q38664453-A8D84F39-7CA2-48AE-8BBF-E1CBEFDBFBADQ38789871-200D7EC4-9BD5-4856-AAE3-3A8D179D840AQ38830892-86D54FE2-2689-4615-BAA5-AF63DDD5CC0BQ38839766-1BDC57F3-3BA1-4749-B56E-F7B6917FA850Q38859560-627983F9-AE42-416A-942D-1A6B7899ED3DQ38876972-85D328C4-ADF3-408D-9C7D-EEC614F49544
P921
description
Arzneistoff
@de
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Ombitasviiri
@fi
Ombitasvir
@de
Ombitasvir
@vi
Ombitaswir
@pl
ombitasvir
@en
Омбитасвир
@ru
أمبيتاسفير
@ar
オムビタスビル
@ja
type
label
Ombitasviiri
@fi
Ombitasvir
@de
Ombitasvir
@vi
Ombitaswir
@pl
ombitasvir
@en
Омбитасвир
@ru
أمبيتاسفير
@ar
オムビタスビル
@ja
altLabel
ABT 267
@en
ABT-267
@en
Ombitasvir
@en
dimethyl ([(2S,5S)-1-(4-tert-b ...... butane-1,2-diyl]})biscarbamate
@en
prefLabel
Ombitasviiri
@fi
Ombitasvir
@de
Ombitasvir
@vi
Ombitaswir
@pl
ombitasvir
@en
Омбитасвир
@ru
أمبيتاسفير
@ar
オムビタスビル
@ja
P31
P592
P6366
P661
P662
P665
P683
P117
P1579
P2017
CC(C)[C@@H](C(=O)N1CCC[C@H]1C( ...... )[C@H](C(C)C)NC(=O)OC)NC(=O)OC
P2067
893.505112
P2115
N0000191286
P2275
ombitasvir
@en
P231
1258226-87-7
P233
CC(C)C(C(=O)N1CCCC1C(=O)NC2=CC ...... C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC
P234
1S/C50H67N7O8/c1-30(2)42(53-48 ...... t38-,39-,40-,41-,42-,43-/m0/s1
P235
PIDFDZJZLOTZTM-KHVQSSSXSA-N
P274
C₅₀H₆₇N₇O₈